6533b839fe1ef96bd12a668c
RESEARCH PRODUCT
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy
Federica NovelliMatteo LatorreLetizia VerguraMaria Filomena CaiaffaGianna CamiciottoliGabriella GuarnieriAndrea MatucciLuigi MacchiaAndrea VianelloAlessandra VultaggioAlessandro CeliMario CazzolaPierluigi PaggiaroG. CamiciottoliR. MaselliG. PelaiaM. T. BuscetiE. SabatoM. G. CagnazzoF. ColomboLaura PalumboAldo RavazziC. BuccaM. F. CaiaffaA. BerraC. CalabreseA. A. StanziolaP. SchinoM. Di GioacchinoM. CazzolaA. SegretiE. A. PastorelloG. ScibiliaA. VianelloM. R. MarchiL. PaladiniS. BaglioniM. AbbrittiF. AlmerigognaA. MatucciA. VultaggioE. MaggiP. MaestrelliG. GuarnieriG. SteinhilberM. BonaviaP. RottoliE. BargagliG. SennaM. CaminatiL. MacchiaV. BelliaN. ScichiloneP. PaggiaroF. NovelliL. Vergurasubject
AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHumandescription
Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between poorly controlled and partially or well controlled asthmatics showed a statistically significant higher prevalence of some comorbidities in the first group, namely obesity, gastro-oesophageal reflux disease (GORD), aspirin intolerance and mental disorders (all p < 0.001). Similarly, asthmatics with at least one exacerbation in the last year showed a significantly higher prevalence of obesity, chronic rhinosinusitis, nasal polyps, GORD, and aspirin intolerance (all p < 0.05) than patients without exacerbations. When we selected patients without relevant comorbidities (upper airways disease, GORD, obesity, aspirin intolerance) and not currently smoking (N = 73), the percentage of well or partially controlled asthmatics was significantly higher than in patients with comorbidities (84.9% vs 71.1%, p = 0.02); the rate of asthmatics without exacerbations in the last year was also higher (73.6% vs 51.1%, p = 0.001). During omalizumab treatment, a high percentage of asthmatics obtain a good or partial control of asthma. Comorbidities are associated with the lack of asthma control and persistence of exacerbations.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-01-01 |